Data and Discussion

PEPTIDE LIBRARIES AND PROTEOMICS APPLICATIONS
Proteomics helps to distinguish useful information from the masses of DNA-based microarray data, bringing us closer to understanding the functions of the corresponding protein products. There are at least three main research avenues in modern proteomic studies: (i) bold cataloging initiatives that are still largely focused on protein identifications (such initiatives are coordinated by the Human Proteome Organization and include cataloging all human plasma, liver, and brain proteins); (ii) diagnostic projects aimed at finding biomarkers in body fluids and/or tissue biopsies for monitoring diseases, especially at their early onset (e.g., in the case of cancer, identification of a panel of specific markers or a pattern of changes that would reflect the insurgence of the disease, its progress, and its regression upon specific treatment); and (iii) use of proteomics as the basis for development of new drugs. Almost all drug targets are proteins, thus their profiling upon drug treatment is one of the main aims of the pharmaceutical industry.
All the projects outlined above face a formidable challenge: about 50% of all proteins in any proteome are lowabundance species that fall below the detection limit of current technologies. In principle, two-dimensional (2-D) maps with very high (10-mg) protein loads on large-format 2-D gels may detect 1000 copies per cell of a protein via silver staining. Such amounts probably would not be analyzable by mass spectrometry (MS). In practice, most researchers load <1 mg of protein on a single 2-D gel, so the chances of observing low-abundance proteins with a one-extract, one-gel approach are practically nil. In order to overcome that, a number of pre-fractionation tools have been described, as reviewed in Herbert et al. (1) . Such tools comprise not only all possible chromatographic and electrophoretic methods (especially those based on isoelectric focusing) but also organelle pre-fractionation and immunosubtraction of most abundant species via antibody columns (up to 12 different antibodies mixed in a single column). Other tools much in vogue today regard the capture of classes of proteomes based on their structure or function, such as the specific seizure of the glycoproteome via lectin columns (2), the capture of the phosphoproteome via metal chelator resins or affinity for titanium oxide (3), or via antiphosphoamino acid antibodies (4) . Other techniques focus on charting protein-protein interactions via two main methods: (i) the yeast twohybrid system, which allows mapping of binary or pairwise associations (5), or (ii) affinity capturing methods, coupled to MS identification (6) .
All of the above techniques allow a deeper insight on proteomes, albeit on a narrower scale, by selecting and amplifying some classes or families of proteins. For example, we can discern functions of proteins localized in subcellular organelles or performing given functions within a cell, such as coordinating action in molecular assemblies or acting in pathways for achieving a particular task. Observing the protein expression of genomes in a holistic manner would require methodologies able to achieve (7), and the other is the combinatorial ligand library, known as ProteoMiner (Bio-Rad Laboratories, Hercules, CA, USA), which is the object of the present survey (8) (9) (10) . In the case of HPA, the expression of normal and pathological tissues is studied with antibody-based proteomics. HPA aims to systematically generate high-quality antibodies to all nonredundant human proteins and use these to localize all proteins in human tissues. The nonredundant set of human proteins is defined as one product from each gene locus and is obtained by using epitopes that are common to various protein isoforms. These antibodies are produced by highthroughput methods that involve the cloning and expression of protein-epitope signature tags. In principle, if one were able to produce antibodies against all human proteins, one should be able to map all of them in any tissue or cell population. In practice, release 2.0 of HPA (30 October 2006) contains over 1500 antibodies representing over 1300 different proteins. The goal of obtaining a library comprising all possible antibodies for all possible human proteins is still quite far from being achieved, considering that the entire human genome is comprised of ∼23,000 different genes. In the case of ProteoMiner, the performance and properties of this ligand library will be reported below. Solid phase combinatorial libraries of hexapeptides are synthesized via a modified Merrifield approach, by using the well-known "separate-recombineassemble" method. The process yields a situation where each bead comprises multiple copies of the same peptide and all beads are mixed together. The peptide ligand is grafted throughout the bead's porous structure and can reach a concentration of about 10 to 15 pmole per bead, ensuring a maximum binding capacity ranging from 5 to 10 mg per mL of settled bead bed. Total binding capacity for protein partners per single bead is thus around 1-3 ng depending on the molecular mass. Each single bead, therefore, has millions of copies of a single unique ligand and each bead potentially has a different ligand from every other bead. For details on this technology and library properties, see References 8−10.
The number of diverse ligands depends on the number of amino acids used and the length of the peptide chain. Table 1 gives a representation of the number of potential ligands obtainable.
The hexapeptide library acts on the principle of solid phase affinity adsorption, a well-known chromatographic process for selectively capturing and concentrating a given protein. Its intrinsic limitation is the binding capacity of the sorbent, an essential feature in the present technology. When saturation is reached, the excess unbound protein is discarded in the flow-through. If, instead of using a single ligand, one adopts a pool of affinity ligands, each unique affinity ligand bead will independently bind and concentrate its specific protein up to the point of saturation. When the relative concentrations of each species within the protein mixture encompass a large dynamic range where high-abundance proteins (HAPs) exceed capacity and low-abundance proteins (LAPs) are below the capacity of their respective specific affinity ligands, HAPs will rapidly saturate their corresponding beads while LAPs will continue to adsorb as long as enough sample is available. After removal of all proteins that exceed the binding capacity of the beads, the composition of proteins retained by the beads will be defined by the presence of their specific affinity ligands. The relative concentrations of each retained protein will be defined by the capacity and saturation degree of each of the affinity ligands and the relative starting concentration of each protein species. Considering that the library includes all necessary ligands for the adsorption of all HAPs and LAPs, elution of adsorbed species will result in a new protein mixture where the diversity of proteins is practically unchanged, but their respective concentration difference is much diminished from the initial sample.
This technology has been applied to search for the low-abundance proteome in various biological fluids, such as urine (11), serum (12) , and human platelets lysate (13) , thus greatly expanding the identification of rare species. In another application, this technique has performed extremely well in bringing to the light host proteins and other impurities present in trace amount in biotech products (14, 15) . A recent achievement was the strong reduction of a dominating species while concomitantly amplifying very lowabundance proteins from a red blood cell lysate (16) . For reviews of these applications, see References 8-10.
The previously unpublished processing and 2-D analysis of the human bile proteome showed a reduced concentration range and permitted the detection of lowabundance species. As shown in Figure   Table 1  1  1  1  1  1  1  2  4  8  16  32  64  129  3  9  27  81  243  729  2187  4  16  64  256  1024  4096  16384  5  25  125  625  3125  15625  78125  6  36  216  1296  7776  46656  279936  7  49  343  2401  16807  117649  823543  8  64  512  4096  32768  262144  2097152  9  81  729  6561  59049  531441  4782969  10  100  1000  10000  100000  1000000  10000000  11  121  1331  14641  161051  1771561  19487171  12  144  1728  20736  248832  2985984  35831808  13  169  2197  28561  371293  4826809  62748517  14  196  2744  38416  537824  7529536  105413504  15  225  3375  50625  759375  11390625  170859375  16  256  4096  65536  1048576  16777216  268435456  17  289  4913  83521  1419857  24137569  410338673  18  324  5832  104976  1889568  34012224  612220032  19  361  6859  130321  2476099  47045881  893871739  20  400  8000  160000  3200000  64000000  1280000000 1, compared with control, untreated material displays, via silver staining, a set of most prominent spots in the Mr 50-75 kDa range (plus a heavy spot at around 150 kDa). The samples treated with hexapeptide libraries exhibit a much larger number of spots of similar intensity. Actually, this study added 143 novel proteins to the known bile protein composition, bringing the number to 288 gene products (17) . Since a number of the lowabundance proteins discovered belong to structural groups, it was hypothesized that they were released by bile duct cell death. Variations in the concentrations in these proteins may have pathophysiological significance in the cases of obstructive diseases such as cholangiocarcinoma, a highly lethal cancer that is notoriously difficult to diagnose and treat.
Although bile fluid is difficult to access, it may be interesting for the study of subtle changes while the diagnosis would continue to be made from serum. Similar approaches are currently extensively adopted to increase the probability of finding biomarkers of relevance for a number of other pathologies. 
